Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

Immune therapies keep working after the infusion ends - both their benefit and their danger. Checkpoint inhibitors, CAR T-cell therapy, bispecific antibodies, and cytokines cause inflammatory toxicity that overlaps with infection, progression, embolism, and endocrine failure. The RN triage question is: could this symptom be immune-related and urgent?

Immune-Related Adverse Events

Immune-related adverse events (irAEs) from checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) can strike skin, bowel, liver, lungs, kidneys, endocrine glands, heart, or nerves, and may appear weeks to months after therapy ends.

Immune-related myocarditis is rare but carries high mortality and must be escalated immediately. The cornerstone of management for moderate-to-severe irAEs is to hold the immunotherapy and start corticosteroids, with hormone replacement for endocrinopathies (which often is permanent). A key safety rule: do not tell patients to self-start steroids or antidiarrheals unless that is their specific plan from the oncology team.

Cytokine Release Syndrome

Cytokine release syndrome (CRS) is a systemic inflammatory response most associated with CAR T-cell therapy and bispecific antibodies. Fever (38.0 C or higher) is the defining first sign. The ASTCT consensus grading scales CRS by fever plus hypotension and hypoxia:

CRS can look exactly like sepsis, and both are treated urgently while the cause is sorted out. Nursing actions: frequent vitals, continuous pulse oximetry, mental-status checks, intake and output, telemetry, cultures and antibiotics if infection is possible, and rapid notification. Tocilizumab (an IL-6 receptor blocker) is the targeted therapy for significant CRS, with corticosteroids, fluids, oxygen, and vasopressors as needed. Treat any fever after cellular therapy or a bispecific antibody as urgent until the team says otherwise.

ICANS and the ICE Score

Immune effector cell-associated neurotoxicity syndrome (ICANS) is neurotoxicity after immune-effector therapy. Early signs are subtle: handwriting change, word-finding difficulty, tremor, slowed responses, impaired attention, or mild confusion. Severe ICANS brings aphasia, somnolence, seizures, motor weakness, cerebral edema, and coma. Grade it with the 10-point Immune Effector Cell-Associated Encephalopathy (ICE) tool: orientation to year, month, city, hospital (4 points); naming 3 objects (3 points); following a command (1 point); writing a standard sentence (1 point); and attention by counting backward from 100 by 10 (1 point).

A falling ICE score, declining consciousness, seizure, or cerebral edema raises the grade. Implement seizure and fall precautions, assess swallowing and airway, avoid sedating medications unless ordered, and escalate any change. ICANS may follow CRS or appear independently.

Urgent Triage and Education

Effective triage starts by identifying the therapy - ask for the treatment card, product name, infusion or step-up date, and emergency instructions. Triage conservatively: a fever after a bispecific antibody is not just a fever until CRS and infection are considered; new confusion after CAR T-cell therapy is not fatigue until ICANS, sepsis, and metabolic causes are ruled out. Teach patients to carry their wallet card, avoid driving during the restricted period after cellular therapy, stay near the treating center if instructed, and call immediately for fever, dizziness, dyspnea, confusion, tremor, speech change, or seizure.

Caregivers are essential observers - include them in every teaching session and handoff, which should list the product, date and cycle, time from infusion, baseline neuro status, vital-sign trends, and whether the cell-therapy team has been contacted.

Timing, Overlap, and the Conservative Mindset

Timing is a powerful triage clue across these immune emergencies. CRS typically begins within the first several days after CAR T-cell infusion, and ICANS often follows CRS, frequently peaking a few days later, though either can occur alone. Checkpoint-inhibitor irAEs behave differently - they can appear after a single dose or emerge months into therapy and even after it stops, so a patient presenting to the emergency department with new colitis or hepatitis weeks after immunotherapy may not connect the symptom to the drug unless the nurse asks.

Always reconstruct the treatment timeline: product, last dose, step-up status, and any restricted activity period.

The disciplined mindset for immune emergencies is conservative escalation, because early symptoms are easy to mislabel and the consequences of missing them are severe. A low-grade fever after a bispecific antibody is CRS until infection is excluded; new word-finding trouble after cellular therapy is ICANS until proven otherwise; new diarrhea after a checkpoint inhibitor is immune colitis until infection and dehydration are assessed; and chest pain or new dyspnea after immunotherapy must raise myocarditis, which can be fatal.

The nurse's job is not to grade or name the syndrome alone but to recognize the pattern, apply the validated tools such as ICE scoring, and bring the cell-therapy or immunotherapy team to the bedside fast, with caregivers engaged as essential observers throughout.